1887

Journal of General Virology header logo

Volume 75, Issue 7

Analysis of the thymidine kinase of a herpes simplex virus type 1 isolate that exhibits resistance to (E)-5-(2-bromovinyl)-2′-deoxyuridine Free

Abstract

The mechanism responsible for the decreased sensitivity of a clinical herpes simplex virus type 1 (HSV-1) isolate, HSV-145, to (E)-5-(2-bromovinyl)-2′-deoxyuridine (BVDU) was examined. Measurements of 50% inhibitory doses of several drugs demonstrated that although HSV-145 was sensitive to phosphonoacetic acid, adenine arabinoside and acyclovir, its sensitivity to BVDU and 5-(2-chloroethyl)-2′-deoxyuridine was significantly less than that normally observed for HSV-1. Analysis of the thymidylate kinase (TMP-K) activity of HSV-145 thymidine kinase (TK) demonstrated a decreased level of TMP-K activity when compared to HSV-1 TK. The TMP-K activity of HSV-145 resembled that observed for HSV-2 and the TK-deficient strain HSV-1 TK. When the nucleotide sequence of the HSV-145 TK gene was compared to that of the HSV-1 strains Cl(101) and SC16 a single nucleotide substitution (G changed to A at base position 502) was detected which would result in the substitution of threonine at amino acid position 168 for alanine. The substitution is the same as that for the laboratory- derived BVDU-resistant virus HSV-1 SC16B3. Collectively, these studies highlight the importance of amino acid conservation at position 168 of the HSV-1 TK in conferring efficient TMP-K activity and BVDU sensitivity.

  • Received:
  • Accepted:
  • Published Online:
© The Journal of General Virology 1994
Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-75-7-1743
1994-07-01
2024-04-23
Loading full text...

Full text loading...

/deliver/fulltext/jgv/75/7/JV0750071743.html?itemId=/content/journal/jgv/10.1099/0022-1317-75-7-1743&mimeType=html&fmt=ahah

References

  1. Allandeen H. S., Kozarich J. W., Bertino J. R., Declercq E. 1981; On the mechanism of selective inhibition of herpesvirus replication by (E)-5-(2-bromovinyl)-2′-deoxyuridine. Proceedings of the National Academy of Sciences, U.S.A 78:2698–2702
     [Google Scholar]
  2. Ayisi N. R., Wall E., De Clercq E., Sacks S. 1985; Differential metabolism of (E)-5-(2-bromovinyl)-2′-deoxyuridine in wild-type and drug-resistant herpes simplex virus-infected cells. Antiviral Research supplement 1 45–49
     [Google Scholar]
  3. Bernaerts R., Desgranges C., De Clercq E. 1989; (E)-5-(2-bromovinyl) uridine requires phosphorylation by the herpes simplex virus (type 1)-induced thymidine kinase to express its antiviral activity. Biochemical Pharmacology 38:1955–1961
     [Google Scholar]
  4. Chen M. S., Prusoff W. H. 1974; A new rapid assay for measuring deoxycytidylate- and deoxythymidylate-kinase activities. Analytical Biochemistry 60:545–550
     [Google Scholar]
  5. Chen M. S., Prusoff W. H. 1978; Association of thymidylate kinase activity with pyrimidine deoxyribonucleoside kinase induced by herpes simplex virus. Journal of Biological Chemistry 253:1325–1327
     [Google Scholar]
  6. Cheng Y.-C., Dutschman G., De Clercq E., Jones A. S., Rahim S. G., Verhelst G., Walker R. T. 1981; Differential affinities of 5-(2-halogenovinyl)-2′-deoxyuridines for deoxythymidine kinases of various origins. Molecular Pharmacology 20:230–233
     [Google Scholar]
  7. Coen D. M., Irmiere A. F., Jacobson J. G., Kerns K. M. 1989; Low levels of herpes simplex virus thymidine-thymidylate kinase are not limiting for sensitivity to certain antiviral drugs or for latency in a mouse model. Virology 168:221–231
     [Google Scholar]
  8. Darby G., Larder B. A., Inglis M. M. 1986; Evidence that the ‘activecentre’ of the herpes simplex virus thymidine kinase involves an interaction between three distinct regions of the polypeptide. Journal of General Virology 67:753–758
     [Google Scholar]
  9. De Clercq E., Descamps J., De Somer P., Barr P. J., Jones A. S., Walker R. T. 1979; (E)-5-(2-bromovinyl)-2′-deoxyuridine: a potent and selective anti-herpes agent. Proceedings of the National Academy of Sciences, U.S.A 76:2947–2951
     [Google Scholar]
  10. De Clercq E., Descamps J., Verhelst G., Walker R. T., Jones A. S., Torrence P. F., Shugar D. 1980; Comparative efficacy of antiherpes drugs against different strains of herpes simplex virus. Journal of Infectious Diseases 141:563–574
     [Google Scholar]
  11. De Clercq E., Bernaerts R., Merta A., Rosenwirth B. 1990; Mechanism of action of 5-(2-chloroethyl)-2′-deoxyuridine, a selective inhibitor of herpes simplex virus replication. Molecular Pharmacology 37:658–664
     [Google Scholar]
  12. Docherty J. J., Goldberg R. J., Rapp F. 1971; Differential effect of 7,12-dimethylbenz[a]anthracene on infectivity of herpes simplex virus type 2. Proceedings of the Society for Experimental Biology and Medicine 136:328–333
     [Google Scholar]
  13. Docherty J. J., Dobson A. T., Trimble J. J., Jennings B. A. 1991; Herpes simplex virus type 1 that exhibits herpes simplex type 2 sensitivity to (E)-5-(2-bromovinyl)-2′-deoxyuridine. Intervirology 32:308–315
     [Google Scholar]
  14. Elion G. B., Furman P. A., Fyfe J. A., De Miranda P., Beauchamp L., Schaeffer H. J. 1977; Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl)guanine. Proceedings of the National Academy of Sciences, U.S.A 74:5716–5720
     [Google Scholar]
  15. Field H. J., Neden J. 1982; Isolation of bromovinyldeoxyuridine-resistant strains of herpes simplex virus and successful chemotherapy of mice infected with one such strain using acyclovir. Antiviral Research 2:243–254
     [Google Scholar]
  16. Furman P. A., St Clair M. H., Fyfe J. A., Rideout J. L., Keller P. M., Elion G. B. 1979; Inhibition of herpes simplex virus- induced DNA polymerase activity and viral DNA replication by 9-(2-hydroxyethoxymethyl)guanine and its triphosphate. Journal of Virology 32:72–77
     [Google Scholar]
  17. Fyfe J. A. 1982; Differential phosphorylation of (E)-5-(2-bromovinyl)-2′-deoxyuridine monophosphate by thymidylate kinases from herpes simplex viruses types 1 and 2 and varicella zoster virus. Molecular Pharmacology 21:432–437
     [Google Scholar]
  18. Fyfe J. A., Keller P. M., Furman P. A., Miller R. L., Elion G. B. 1978; Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound, 9-(2-hydroxyethoxymethyl)-guanine. Journal of Biological Chemistry 253:8721–8727
     [Google Scholar]
  19. Fyfe J. A., Mckee S. A., Keller P. M. 1983; Altered thymidine-thymidylate kinases from strains of herpes simplex virus with modified drug sensitivities to acyclovir and (E)-5-(2-bromovinyl)-2′-deoxyuridine. Molecular Pharmacology 24:316–323
     [Google Scholar]
  20. Haarr L., Flatmark T. 1987; Evidence that deletion of coding sequences in the 5′ end of the thymidine kinase gene of herpes simplex virus type 1 affects the stability of the gene products. Journal of General Virology 68:2817–2829
     [Google Scholar]
  21. Jamieson A. T., Gentry G. A., Subak-Sharpe J. H. 1974; Induction of both thymidine and deoxycytidine kinase activity by herpes viruses. Journal of General Virology 24:465–480
     [Google Scholar]
  22. Javier R. T., Thompson R. L., Steven J. G. 1987; Genetic and biological analysis of a herpes simplex virus intertypic recombinant reduced specifically for neurovirulence. Journal of Virology 61:1978–1984
     [Google Scholar]
  23. Lineweaver FI., Burk D. 1934; The determination of enzyme dissociation constants. Journal of the American Chemical Society 56:658–666
     [Google Scholar]
  24. Mao J.C.-H., Robishaw E. E., Overby L. R. 1975; Inhibition of DNA polymerase from herpes simplex virus-infected Wi-38 cells by phosphonoacetic acid. Journal of Virology 15:1281–1283
     [Google Scholar]
  25. Prusoff W. H., Ward D. C. 1976; Nucleotide analogs with antiviral activity. Biochemical Pharmacology 25:1233–1239
     [Google Scholar]
  26. Ruth J. L., Cheng Y.-C. 1981; Nucleoside analogues with clinical potential in antivirus chemotherapy: the effect of several thymidine and 2′-deoxycytidine analogue 5′-triphosphates on purified human (α, β) and herpes simplex virus (types 1, 2) DNA polymerases. Molecular Pharmacology 20:415–422
     [Google Scholar]
  27. Smith K. O., Kennell W. L., Poirier R. H., Lynd F. T. 1980; In vitro and in vivo resistance of herpes simplex virus to 9-(2-hydroxyethoxymethyl)guanine (acycloguanosine). Antimicrobial Agents and Chemotherapy 17:144–150
     [Google Scholar]
  28. Swain M. A., Galloway D. A. 1983; Nucleotide sequence of the herpes simplex virus type 2 thymidine kinase gene. Journal of Virology 46:1045–1050
     [Google Scholar]
  29. Wagner M. J., Sharpe J. A., Summers W. C. 1981; Nucleotide sequence of the thymidine kinase gene of herpes simplex virus type 1. Proceedings of the National Academy of Sciences, U.S.A 78:1441–1445
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-75-7-1743
Loading
Analysis of the thymidine kinase of a herpes simplex virus type 1 isolate that exhibits resistance to (E)-5-(2-bromovinyl)-2′-deoxyuridine
J. Gen. Virol. 75, 1743 (1994); https://doi.org/10.1099/0022-1317-75-7-1743
/content/journal/jgv/10.1099/0022-1317-75-7-1743
/content/journal/jgv/10.1099/0022-1317-75-7-1743
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error